Baseline characteristics
| Characteristic . | All patients (n = 102) . |
|---|---|
| Gender | |
| Female | 43 (42) |
| Male | 59 (58) |
| Underlying disorder | |
| None/idiopathic | 68 (67) |
| Autoimmunity | 20 (20) |
| Malignancy | 13 (13) |
| Pregnancy | 5 (5) |
| Concomitant disorders | |
| Coronary artery disease | 28 (27) |
| Heart failure | 30 (29) |
| Renal failure | 37 (36) |
| Arterial hypertension | 59 (58) |
| Diabetes mellitus type 2 | 28 (27) |
| WHO-PS | |
| 0 | 15 (15) |
| 1 | 26 (25) |
| 2 | 23 (23) |
| 3 | 22 (22) |
| 4 | 15 (15) |
| 5 | 1 (1) |
| Age in y, median (range) | 74 (26-97) |
| FVIII activity in IU/dL, median (range) | 1.4 (<1-31) |
| Inhibitor concentration in BU/mL, median (range) | 19 (1-1449) |
| Characteristic . | All patients (n = 102) . |
|---|---|
| Gender | |
| Female | 43 (42) |
| Male | 59 (58) |
| Underlying disorder | |
| None/idiopathic | 68 (67) |
| Autoimmunity | 20 (20) |
| Malignancy | 13 (13) |
| Pregnancy | 5 (5) |
| Concomitant disorders | |
| Coronary artery disease | 28 (27) |
| Heart failure | 30 (29) |
| Renal failure | 37 (36) |
| Arterial hypertension | 59 (58) |
| Diabetes mellitus type 2 | 28 (27) |
| WHO-PS | |
| 0 | 15 (15) |
| 1 | 26 (25) |
| 2 | 23 (23) |
| 3 | 22 (22) |
| 4 | 15 (15) |
| 5 | 1 (1) |
| Age in y, median (range) | 74 (26-97) |
| FVIII activity in IU/dL, median (range) | 1.4 (<1-31) |
| Inhibitor concentration in BU/mL, median (range) | 19 (1-1449) |
Values are n (%) unless otherwise noted.